Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRAIL-modified adipose-derived stem cells
- Development stage
- Preclinical
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intratumoral, Possible Intravenous Or Local Administration In Future Clinical Development
01
Overview
**TRAIL-modified adipose-derived stem cells** are human adipose-derived mesenchymal stem cells that have been genetically engineered to express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily. The purpose of this modification is to enable these stem cells to deliver TRAIL directly to tumor environments, exploiting both the homing capacity of adipose-derived stem cells (ADSCs) for tumors and the selective apoptotic activity of TRAIL on cancer cells while sparing normal cells. The secreted TRAIL protein from transfected ADSCs induces caspase-mediated apoptosis in malignant cells (notably melanoma and various solid tumor lines) via activation of death receptors, downregulation of survival pathways such as PI3K-AKT, and activation of caspase-3, -4, -8, and -9[1]. This approach is an experimental targeted cell-based gene therapy, not approved or marketed, and remains at the preclinical research stage.
- Other names
- TRAIL-ADSCsADSC-TRAILTRAIL-engineered adipose-derived stem cells
02
Targets
TNFRSF10A (Death receptor 4)
Beyond the preview
Go deeper on TRAIL-modified adipose-derived stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRAIL-modified adipose-derived stem cells.